Findings published in the December 1, 2008, issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit. In addition, a misclassification of metastatic breast cancer patients by as much as 10 percent prevents some people from receiving optimal therapy.
- HER2 levels may aid in treatment selection for metastatic breast cancerTue, 2 Dec 2008, 10:49:47 EST
- Targeted therapy prolongs life in patients with HER2-positive breast cancerFri, 11 Dec 2009, 13:59:03 EST
- Targeted agent addition to herceptin has positive effect on metastatic HER-2 breast cancerFri, 8 Jul 2011, 19:34:55 EDT
- Targeted therapy promising for HER2-positive metastatic breast cancerFri, 8 Oct 2010, 12:06:07 EDT
- Scientists developing new therapy for HER2-positive breast cancerTue, 26 Jul 2011, 17:35:00 EDT